PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

[1]  Charles M. Perou,et al.  Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.

[2]  Zhiyuan Hu,et al.  Systematic Bias in Genomic Classification Due to Contaminating Non-neoplastic Tissue in Breast Tumor Samples , 2011, BMC Medical Genomics.

[3]  C. Perou,et al.  Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer , 2011, Breast Cancer Research and Treatment.

[4]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[5]  S. Paik,et al.  Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[7]  E. Álava,et al.  Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer , 2010, Breast Cancer Research and Treatment.

[8]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[9]  G. Hortobagyi,et al.  Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Shou-Ching Tang.  Taxanes in the Adjuvant Treatment of Early Breast Cancer, Emerging Consensus and Unanswered Questions , 2009, Cancer investigation.

[14]  D. Larsimont,et al.  Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel , 2008, Clinical Cancer Research.

[15]  Arrate Plazaola,et al.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. , 2008, Journal of the National Cancer Institute.

[16]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[17]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Larsimont,et al.  HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  F. Cognetti,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2008, The New England journal of medicine.

[20]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Pelicano,et al.  Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. , 2007, Cancer research.

[22]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[23]  J. Mackey,et al.  Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. , 2007, Breast.

[24]  Donald Berry,et al.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.

[25]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[26]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Milella,et al.  Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.

[28]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[29]  F. Monzon.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[30]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Russo,et al.  Erratum: Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index (Modern Pathology (2005) 18 (1067-1078) DOI: 10.1038/modpathol.3800388) , 2005 .

[32]  Andrew Glass,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[33]  Roman Rouzier,et al.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[35]  J. Russo,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[36]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[37]  M. Untch,et al.  Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.

[38]  G. Hortobagyi,et al.  Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma , 2004, Cancer.

[39]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Stockler,et al.  Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.

[41]  M. Monden,et al.  Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  D. Larsimont,et al.  Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. , 2002, Clinical breast cancer.

[43]  C. Hudis,et al.  Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[45]  H Donis-Keller,et al.  The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  J F Simpson,et al.  Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  T. K. Yeung,et al.  The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. , 1999, Biochemical and biophysical research communications.

[48]  L. Xue,et al.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. , 1999, Cancer biotherapy & radiopharmaceuticals.

[49]  S. Horwitz.  Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  H. Koelbl,et al.  Adjuvant chemotherapy of early breast cancer. , 2012, The Medical letter on drugs and therapeutics.

[51]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.